AMRN

The patent war between Amarin (NASDAQ: AMRN) and the generic companies for cardiovascular drug Vascepa continues to be a headwind…

Amarin Corporation plc  (AMRN) Q1 2020 earnings call dated Apr. 30, 2020 Corporate Participants: Elisabeth Schwartz — Senior Director of Investor Relations…

Shares of Amarin Corporation plc (NASDAQ: AMRN) were up 4.6% in midday trade on Tuesday, a day after the company…

Amarin Corporation plc  (AMRN) Q1 2020 earnings call dated Apr. 13, 2020 Corporate Participants: Elisabeth Schwartz — Senior Director of Investor Relations…

Amarin Corporation plc  (NASDAQ: AMRN) Q4 2019 Earnings Conference Call February 25, 2020 Corporate participants: Elisabeth Schwartz — Senior Director of Investor…

— Amarin Corporation plc (NASDAQ: AMRN) reported earnings of $0.04 per share in the fourth-quarter 2019 vs. $0.02 per share loss expected.   —…

Though Amarin Corporation (NASDAQ: AMRN) has been showing signs of recovery since last year, after staying low for several years,…

Biotech firm Amarin Corporation (NASDAQ: AMRN) had a positive start to the week, with the shares making sharp gains and…